摘要
2021年7月,世界卫生组织发布了《世界卫生组织子宫颈癌癌前病变筛查和治疗指南(第2版)》,该指南明确提出在筛查策略中将人乳头瘤病毒(human papilloma virus,HPV)DNA检测作为子宫颈癌的初筛方法。将筛查女性分为一般人群和感染人类免疫缺陷病毒人群,并实施筛查-治疗和筛查-分流-治疗策略,筛查年龄分别从30岁和25岁开始,至49岁。根据筛查和分流阳性结果予以治疗,并对随访做出详细规定。本文对指南内容作一解读。
In July 2021,the World Health Organization(WHO)released WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention,second edition,which explicitly recommends human papilloma virus(HPV)DNA testing as a primary screening method for cervical cancer screening.The screening women were divided into the general population and women living with human immunodeficiency virus,and the screening-treatment and screening-triage-treatment strategies were implemented,starting at 30 and 25 years of age,respectively,to 49 years of age.Positive screening and triage results were used for treatment,and follow-up was specified in detail.This paper makes an interpretation of the contents of the guidelines.
作者
魏丽惠
李明珠
王悦
Wei Lihui;Li Mingzhu;Wang Yue(Department of Gynaecology,Peking University People's Hospital,Beijing 100044,China)
出处
《中国医学前沿杂志（电子版）》
2021年第9期44-48,共5页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金
国家重点研发计划(2016YFC1302901)
北京大学人民医院研究与发展基金(RDL2020-02)。
关键词
子宫颈癌癌前病变
筛查
治疗
子宫颈癌预防
Cervical pre-cancer lesions
Screening
Treatment
Cervical cancer prevention
